Arrowhead Research Subsidiary, Nanopolaris, Changes Name to Unidym
PASADENA, California – (BUSINESS WIRE) – July 25, 2006 – Arrowhead Research Corporation (Nasdaq:ARWR), announced today that its majority-owned subsidiary, NanoPolaris, has changed its name to Unidym. The company will continue to execute its strategy of building a patent portfolio related to carbon nanomaterials and commercializing new carbon-based electronic products. The company's first product is a transparent and electrically conductive nanotube film that addresses the estimated one billion dollar market opportunity to replace indium tin oxide (ITO) in a variety of applications, including touch screens, flat panel displays, and solar cells.
"Unidym has already shipped sample films," explained R. Bruce Stewart, Chairman and CEO of Arrowhead. "We changed NanoPolaris' name to Unidym to leverage the market traction that the Unidym team had achieved prior to Unidym's acquisition by NanoPolaris."
Unidym develops novel materials architectures that will further enhance the areas of electronics, optoelectronics and photovoltaics. The technology is based on films of carbon nanotubes, leading to high electrical conductivity, mechanical flexibility, transparency, and environmental resistance. Subsequent products are planned for applications that include low cost, flexible electronic devices based on carbon, such as displays that roll up or RFID tags.
Unidym is located in Los Angeles, California. For more information please visit www.unidym.com.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statement on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts
Virginia Dadey; Vice President, Investor Relations
Telephone: 212.541.3707
Email: vdadey@arrowres.com